article thumbnail

Merck KGaA to buy gene therapy tools maker for $600M

Bio Pharma Dive

The German drugmaker is bolstering its MilliporeSigma business with a unit of Gamma Biosciences that specializes in so-called transfection reagents.

article thumbnail

Teknova unveils new manufacturing facility for high-quality reagents

BioPharma Reporter

Teknova, a producer of life science reagents, has opened a new GMP-certified production facility which it claims will enable bioprocessing and gene therapy companies to get into the clinic faster.

Reagent 88
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nektar Therapeutics to sell Alabama facility to Ampersand

Pharmaceutical Technology

Nektar has signed a definitive agreement to divest its Huntsville facility and associated reagent supply business to Ampersand

Reagent 130
article thumbnail

BMS and Prime ink potential $3.5bn deal to develop T cell therapies

Pharmaceutical Technology

As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime Medicine.

Reagent 130
article thumbnail

Danaher to buy antibody supplier Abcam for $5.7B

Bio Pharma Dive

The acquisition gives Danaher ownership of a producer of research tools, such as antibodies and reagents, that are used in drug discovery experiments.

Antibody 130
article thumbnail

Merck builds in cell, gene therapies with Mirus Bio deal

pharmaphorum

Merck KGaA has agreed to a $600m deal to buy Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies.

article thumbnail

Bill & Melinda Gates Foundation funding for MIP Discovery

Pharma Times

Boost concerns rapid deployment of novel detection reagents for testing in low to middle-income countries

Reagent 120